Background: SaltSwitch is an innovative smartphone application (app) that enables shoppers to scan the barcode of a packaged food and receive an immediate, interpretive, traffic light nutrition label on the screen, along with suggestions for lower salt alternatives. Our aim was to determine the effectiveness of SaltSwitch to support people with cardiovascular disease to make lower salt food choices. Design: Six-week, two-arm, parallel, randomised controlled trial in Auckland, New Zealand (2 weeks baseline and 4 weeks intervention). Methods: Sixty-six adults with diagnosed cardiovascular disease (mean (SD) age 64 (7) years) were randomly assigned in a 1:1 ratio to either the SaltSwitch smartphone app or control (usual care). The primary outcome was the salt content of household packaged food purchases during the 4-week intervention (g/MJ). Secondary outcomes were the saturated fat content (g/MJ), energy content (kJ/kg) and expenditure (NZ$) of household food purchases; systolic blood pressure (mmHg), urinary sodium (mg) and use and acceptability of the SaltSwitch app. Results: Thirty-three participants with cardiovascular disease were allocated to the SaltSwitch intervention, and 33 to the control group. A significant reduction in mean household purchases of salt was observed (mean difference (95% confidence interval), À0.30 (À0.58 to À0.03) g/MJ), equating to a reduction of $0.7 g of salt per person per day during the 4-week intervention phase. There were no significant between-group differences in any secondary outcomes (all P > 0.05). Conclusions: The SaltSwitch smartphone app is effective in supporting people with cardiovascular disease to make lower salt food purchases. A larger trial with longer follow-up is warranted to determine the effects on blood pressure.
Introduction
Effective interventions to reduce the incidence of cardiovascular disease (CVD) events are vital, especially for those who have experienced an event in the past. 1 People with existing CVD are advised to eat a lower salt diet to reduce and control blood pressure (BP), 2 ,3 yet global and national salt intakes are far above recommendations in most countries 4 and many find it hard to identify lower salt food choices. 5 Cardiac rehabilitation programmes offer support to achieve lower salt diets, but uptake in most countries is poor, largely due to access issues. 6 Mobile technology may offer part of the solution. A growing body of evidence indicates mobile technology can support behaviour change, 7 ,8 yet robust evidence for the effectiveness of smartphone interventions is lacking. 9 SaltSwitch is a feature of the free FoodSwitch smartphone app, 10 which enables users to scan the barcode of a packaged food with their smartphone camera to receive an immediate, interpretive traffic light nutrition label on the screen, along with a list of lower salt alternatives to 'switch' to ( Figure 1) .
The primary aim of this study was to determine the short-term effectiveness of the SaltSwitch smartphone app in supporting people with CVD to make lower salt food choices. Secondary aims were to determine the effectiveness of SaltSwitch in reducing the saturated fat content, energy content, and expenditure of household food purchases. Systolic blood pressure (BP) (mmHg), urinary sodium (mg), and use and acceptability of the SaltSwitch app were also assessed.
Methods

Study design
The SaltSwitch trial was a 6-week, two-arm, parallel, randomised controlled trial. A 2-week baseline data collection phase was followed by a 4-week intervention phase.
The trial was conducted between June 2014 and July 2015 in Auckland, New Zealand. The study protocol was approved by the University of Auckland Human Ethics Committee (reference 010998) and published in 2014. 11 All participants provided written, informed consent.
Participants
The unit of randomisation for the trial was the person with CVD. However, the primary outcome was household food purchases. Therefore, when the person with CVD did not complete most of the grocery shopping, the main household shopper was also enrolled.
Participants were included if they were diagnosed with CVD and aged 40 years or over. CVD was defined as having a diagnosed history of prior acute coronary syndrome (ACS), revascularisation or exertion angina. Participants were excluded if they had experienced a cardiac event (hospitalisation for ACS, coronary revascularisation procedure, or stroke) in the past 3 months, been diagnosed with heart failure or severe valve disease, be on a physician supervised diet or unwilling to make dietary changes, or taking any medication that could lead to hyponatraemia or fluid retention (furosemide, regular non-steroidal anti-inflammatories (excluding aspirin), or regular prednisone use).
Main household shoppers had to own or have access to a smartphone (iPhone or Android) but could not be current users of the FoodSwitch smartphone app or be planning to use it during the following 6 weeks. To provide enough data for outcomes assessment, shoppers had to shop at the supermarket for household food at least once per week spending NZ$25 or more per household member, and return at least two till receipts over the 2-week baseline period. When the main household shopper was different to the participant with CVD, they had to be at least 18 years of age. All participants were required to be resident at their usual address in Auckland, New Zealand for at least 39 of the 42 days of the 6-week trial period.
Recruitment
Recruitment took place over 11 months starting in June 2014. Recruitment methods and processes have been described in detail previously. 11 Strategies included: advertisements placed in local supermarkets, hospital waiting rooms, healthcare organisation newsletters, and Facebook; articles in local newspapers; invitations to participants in previous studies at the University of Auckland and members of a market research panel; and presentations at cardiac rehabilitation clinics.
Intervention
The intervention group received the SaltSwitch smartphone app for 4 weeks. SaltSwitch enables users to make lower salt food choices by scanning the barcode of a packaged food using their smartphone camera to receive an immediate interpretive, traffic light nutrition label on screen, along with a list of lower salt alternatives to 'switch' to ( Figure 1 ). Further information regarding the SaltSwitch app has been reported previously 11 and is available on the FoodSwitch website.
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Participants in the intervention group were emailed a link to download the SaltSwitch app to their smartphone and were provided with a telephone tutorial. Weekly reminder text messages were sent to intervention participants to encourage them to use the app when shopping for household food and beverages.
Controls
Those randomly assigned to the control group continued to shop as normal and were able to access usual care cardiac rehabilitation services for people with CVD in New Zealand. On completion of the trial, control participants were provided with information about the FoodSwitch app and given the option to download it.
Outcomes and data collection Study outcomes. The primary outcome was the salt content of household food purchases (g/MJ) during the 4-week intervention. Secondary outcomes were the saturated fat content (g/MJ), energy content (kJ/kg) and expenditure (NZ$) of household food purchases during the intervention. Systolic BP (mmHg), urinary sodium (mg) and use and acceptability of the SaltSwitch app were also assessed at the end of the intervention. Post-hoc analyses were undertaken on the total fat (g/MJ), protein (g/MJ) and sugar content (g/MJ) of household food purchases, and purchases of key food groups known to be high in salt.
Data collection and outcome measurement. Detailed information on data collection and outcome measurements has been reported previously.
11 Data collection took place over 13 months starting in June 2014. Briefly, till receipts for all household food purchased during the trial period were returned to researchers via the post in pre-paid envelopes, or at clinic visits. Two online questionnaires (baseline and end of intervention) were completed either by clicking on a link sent in an email, or during clinic visits. Participants received a NZ$20 petrol voucher following successful completion of each questionnaire as a reimbursement for their costs in participating in the study. Clinical measures were collected at two visits (baseline and end of study) to the University of Auckland. Participants provided written, informed consent, and height, weight and BP were measured. A random (spot) urine sample for sodium analyses was also collected. Spot urine concentration was converted into an estimate of 24-hour sodium excretion using the INTERSALT formula. 13 The primary outcome (salt content of household food purchases) and secondary outcomes related to shopping purchases (saturated fat content, energy content and expenditure on food) were assessed by matching foods recorded on supermarket till receipts to a brand-specific food composition database from the SaltSwitch app (see Intervention section above). Data on the use and acceptability of the app were collected via on-line questionnaires.
11 Data on serious adverse events was collected at 6 weeks.
Randomisation and blinding
Registered participants were excluded from the study prior to randomisation if they did not spend at least NZ$25 per household member per week on groceries/ food, or returned fewer than two till receipts over the run-in (baseline) trial period.
Eligible participants were randomly assigned at the end of baseline (week 2) in a 1:1 ratio to receive either the SaltSwitch smartphone app or control (usual care). Computer-generated randomisation lists were created by the study statistician (YJ) and sealed in individual opaque envelopes not accessible by the statistician or investigators. Randomisation was stratified by the ethnic (Maori or non-Maori) and age group (40-59 years and 60 þ years) of the participant with CVD, using variable block sizes of two and four. Due to the nature of the intervention, it was not possible to blind participants or outcome assessors.
Sample size and statistical analysis
Sample size. A total sample size of 300 participants with CVD (150 per group) was estimated to provide 80% power at 5% level of significance (two-sided) to detect a treatment difference of 0.07 g/MJ ($10%) of salt in household food purchases, between the two groups at the end of the intervention, assuming a standard deviation (SD) of 0.22 g/MJ. The assumed difference was based on intervention effects achieved in the Dietary Approaches to Stop Hypertension (DASH) study. 14 Further information is available in the study protocol.
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Statistical analysis. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided at a 5% significance level. Baseline characteristics were summarised using descriptive statistics. Continuous variables were presented as mean and SD. Categorical variables were presented as frequencies and percentages.
Evaluation of the treatment effect was performed using the intention-to-treat principle with all participants analysed according to the group they were randomly assigned to, regardless of whether they received the intervention. Missing outcome data were not imputed as it was difficult to make assumptions about the missingness of supermarket till receipt data. Analysis of covariance (ANCOVA) regression models were used to evaluate the main treatment effect on all outcomes during the intervention, adjusting for baseline, age and sex. Model-adjusted means and their difference between the two treatment groups were estimated and tested.
Results Recruitment
Four hundred and sixty-three participants registered for the study, of which 205 (44%) did not meet the inclusion criteria, 149 (32%) declined to participate on hearing more about the study, and 43 (9%) were excluded for other reasons, such as failing to complete baseline questionnaires ( Figure 2 ). The main reason participants did not meet the inclusion criteria is that they did not have diagnosed CVD (most had high BP only), and/or own a smartphone. The main reason eligible participants declined to participate was lack of interest in taking part in a smartphone intervention. A total of 66 participants with diagnosed CVD were included in the trial, of which 33 were randomly assigned to the SaltSwitch app intervention group and 33 to the control group. All participants provided data for the primary outcome ( Figure 2 ). However, one participant in each group did not attend the final clinic appointment, resulting in BP and urinary sodium measures being missing for these two participants. The trial was stopped before the projected 300 participants with CVD were recruited due to recruitment rates being much slower than predicted, and funding for extending the trial further could not be obtained.
Baseline characteristics of households and participants
At baseline there were 66 participants with diagnosed CVD (33 in each group) and 12 participants who were enrolled in the study as main household shoppers only (seven in the control group and five in the intervention group).
Participants with CVD had a mean (SD) age of 64 (7) years, were predominantly men (n ¼ 55; 83%), had a mean body mass index (BMI) of 29 (4) kg/m 2 , mean systolic BP of 132 (15) mmHg, and an estimated mean 24-hour urinary sodium excretion of 3465 (828) mg. The majority were New Zealand European (n ¼ 55; 88%). Characteristics of participants with CVD were similar between groups (Table 1) .
At the household level, most had an annual income of more than NZ$50,000 (n ¼ 48; 68% of those who answered), lower than the median household income in New Zealand (NZ$73,500 in 2013). 15 The mean (SD) household size was two (one) people. Fourteen of the 66 households (21%) had at least one member with diabetes, and 27 (41%) had members with other medical conditions affecting the type of household food purchased. Similar numbers of shoppers reported using nutrition labels often or every time when shopping for food (n ¼ 31; 47%) versus those who only occasionally or never used nutrition labels (n ¼ 35; 53%). The only major difference observed between groups was for baseline household food expenditure (NZ$162 per week in the control group and NZ$102 per week in the SaltSwitch intervention group; Table 1 ).
Till receipt return, product purchases and household expenditure
Overall, participants returned on average 4.3 till receipts during the 2-week baseline period and 7.2 receipts during the 4-week follow-up period. The average till receipt return rate was lower in the SaltSwitch intervention compared with the control group at both baseline and intervention (3.8 and 6.4, vs. 4.9 and 8.0, respectively). The total number of products purchased over the baseline period was also lower in the SaltSwitch group compared with the control group at baseline (n ¼ 47 (27) and n ¼ 72 (40), respectively) and intervention (n ¼ 90 (51) and n ¼ 115 (64), respectively). Of the 64 participants who completed the follow-up survey, the majority reported returning all or most till receipts for household food or beverages purchased during the 4-week intervention period (n ¼ 31/32 and n ¼ 29/32 for the intervention and control groups, respectively).
Participants spent on average NZ$129.90 (SD, 84.50) per week on household groceries during the baseline period and NZ$119.40 (78.20) per week during follow-up, for a mean (SD) household size of two (one). Participants in the control group spent more per week than those in the intervention group (mean (SD); NZ$162 (94) and NZ$102 (65)).
Till receipt matching
Overall, 1964 food and beverage products (units) were purchased over the baseline period and 3807 over the intervention period (1234 and 2336 unique barcodes, respectively). Ninety per cent (5225/5771) of total purchased products on till receipts could be matched with an identical product in the SaltSwitch app food and nutrient database. The majority of the remaining 10% (n ¼ 546) belonged to the following five food groups: non-alcoholic beverages (n ¼ 135), alcohol (n ¼ 62), coffee and tea (n ¼ 35), meat and meat products (n ¼ 34) and fruit and vegetables (n ¼ 31).
Serious adverse events
One serious adverse event was reported during the study period but was deemed unrelated to the intervention (onset of chest discomfort while exercising resulting in angioplasty).
Primary end-point salt
Participants using the SaltSwitch smartphone app (n ¼ 33) purchased significantly less salt (adjusted mean (95% confidence interval (CI)); 0.7 (0.52 to 0.88) g/MJ) over the 4-week intervention period compared with those assigned to control (n ¼ 33; adjusted mean (95% CI); 1.00 (0.80 to 1.20) g/MJ; group difference (95% CI) -0.30 (-0.58 to -0.03) g/MJ, P ¼ 0.03) ( Table 2 ).
Other nutrient outcomes
There were no significant differences between intervention and control groups for other nutrient outcomes assessed, i.e. energy density, total fat, saturated fat, protein, or total sugar ( Table 2) . 65 (8) 64 (7) Female (n (%)) 8 (24) 3 (9) Weight (kg) 85 (13) 84 (16) Body mass index (kg/m 2 ) 29 (4) 28 (4) Systolic blood pressure (mmHg) 134 (15) 131 (15) Diastolic blood pressure (mmHg) 79 (9) 80 (10) Estimated 24-hour urinary sodium excretion (mg) 3304 (908) 3625 (716) Ethnicity most identify with (n (%)) One household in the control group was an outlier, with very high expenditure on household food (>NZ$400 per week for 4 weeks). One household in the control group failed to return any till receipts.
Systolic BP
Systolic BP at follow-up in the intervention group was mean (95% CI) 129 (125 to 133) mmHg (n ¼ 32). The corresponding value for participants in the control group was 131 (127 to 135) mmHg (n ¼ 32). The mean difference (95% CI) between groups was not statistically significant (À1.7 (À7.4 to 3.9) mmHg; P ¼ 0.54).
Urinary sodium
Estimated urinary sodium excretion at follow-up was mean (95% CI) 3534 (3347 to 3720) mg per day(n ¼ 32). The corresponding value in the control group was 3545 (3358 to 3731) mg per day (n ¼ 32). The mean difference (95% CI) between groups was not statistically significant (À10.6 (À278 to 256) mg per day; P ¼ 0.94).
Household food expenditure
Average weekly household food expenditure (adjusted) in the intervention group was mean (95% CI) NZ$117.93 (95.49 to 140.37). Corresponding expenditure for the control group was NZ$130.01 (105.38 to 154.65). The mean (95%) difference in expenditure between groups was not statistically significant (NZ$-12.08 (À46.98 to 22.82); P ¼ 0.49) ( Table 2 ).
Use and acceptability of the SaltSwitch smartphone app
Of the 30 participants who responded to the question on use of the app (4-point scale), the majority reported that they used the app 'all' or 'most times' they shopped. Use was similar across each of the 4 weeks (percentages were 60%, 75%, 60% and 70%, respectively). Of the 24 participants who responded to the question on the acceptability of the app (five-point scale), 18 (75%) reported finding SaltSwitch very easy to use, and a further four found it somewhat easy to use. One shopper found the app neither difficult nor easy to use, and the remaining shopper found it difficult. All 24 shoppers found SaltSwitch was a good way to help shoppers to make lower salt food purchases.
Discussion
Principal findings
This study has shown that the SaltSwitch app had a significant impact on reducing household purchases of salt from packaged foods. The SaltSwitch app was well used and accepted by the intervention group.
The meaning of study findings
Based on an average of 131 MJ of total energy purchased for each household over the trial period, the 0.3 g/MJ reduction in salt purchases equates to a reduction of $0.7 g per person per day. This is $30% of the reduction reported in the DASH study (2.3 g salt per day).
14 However, reported total energy purchases were much lower than expected, especially over the intervention period, i.e. 2335 kJ per person per day, or 25% of expected (excluding food waste) when compared with the median energy intake in the most recent 2008/2009 New Zealand Adult Nutrition Survey (9158 kJ for men aged 51-70 years). 16 Although till receipts are not a perfect proxy for dietary intakes, 17,18 these estimations Linear regression models estimated the difference between intervention and control groups, adjusted for baseline outcome, age in years, and gender.
suggest the magnitude of salt reduction seen in the SaltSwitch trial is likely to be underestimated.
Strengths and weaknesses of the study
The main strengths of this study include that it is one of a few randomised controlled trials of a smartphone app or mHealth dietary intervention in a clinical population. 7, 8 The trial was conducted in a real world setting with high follow-up rates and objective outcome measures. In addition, the match rate between till receipt purchases and food composition information was high (90%), resulting in the majority of available food purchasing data being used to assess the effects of the intervention on the primary outcome.
Nonetheless, there were limitations, including the fact that spot urine is a relatively poor measure of individual sodium intake compared to 24-hour urine collection, 19 which may have resulted in unreliable estimates. Furthermore, recruitment rates were not met and the study was underpowered based on the initial power calculation. However, the large effect size observed (0.3 g/MJ compared with 0.07 g/MJ in the sample size calculation) means it is unlikely the result is a false positive, and the 66 participants recruited provided at least 80% power to detect a betweengroup difference of 0.15 or more based on the same assumptions as the initial power calculation.
In addition $25% of participants reported that they did not return all receipts for household food and beverages purchased during the intervention period. Furthermore, the till receipt return rates and product purchase numbers were lower in the SaltSwitch group compared with the control group. Nonetheless, the relative outcome measures (g/MJ of salt rather than total salt purchased) mean the groups are still comparable and the missing and unequal till receipt return rates were unlikely to impact the results significantly.
Finally, generalisability may be limited because the initial response rate was low, with 149/463 (32%) of eligible participants declining to participate. The main reason was lack of interest in using a smartphone app. This self-selection bias is a common problem with intervention studies and could reflect the older age of this population group. A recent (2016) systematic review of mobile-health behaviour change interventions for CVD self-management identified only one smartphone trial. 20 In contrast to the current study, the smartphonedelivered intervention had better uptake, adherence and completion rates compared with usual care. However, smartphones were provided to intervention participants and the intervention was a complete CVD package, whereas SaltSwitch only focused on reducing salt intake. Nonetheless, the SaltSwitch randomised controlled trial study design and objective outcome measures mean internal validity for the trial was high and the study findings robust.
Comparison with similar studies
Limited research is available on the efficacy of smartphone interventions to improve self-management of cardiovascular outcomes. 21 However, the modest findings of the SaltSwitch trial align with the results of recent systematic literature reviews in the area. A 2015 review of the impact of mHealth for chronic disease management (n ¼ 107 studies for patients with diabetes, CVD and lung diseases) found high patient acceptability, usability and feasibility for mHealth interventions, but only 16/27 included trials (39%) showed significant between-group improvements. 22 Another 2015 review (n ¼ 51 trials) of the potential benefit of digital health interventions on CVD outcomes and risk factors found digital interventions significantly reduced CVD outcomes, body weight and BMI, but not BP (compared with usual care). 23, 24 As the field of smartphone trials in CVD prevention and treatment grows, further reviews will be important to determine the effects of smartphone apps.
Implications for consumers, clinicians and policy makers
The findings of the SaltSwitch trial suggest that the app has potential to help people with CVD make lower salt food purchases. The SaltSwitch app is currently available to download in several countries (New Zealand, Australia and the United Kingdom), and could be used as a tool for consumers and clinicians globally, the latter of whom could include the app in traditional CVD rehabilitation education sessions as a secondary prevention measure. The proportion of the global adult population with high BP is much higher than the proportion with CVD, 25 and is likely to be younger and possibly more amenable to a smartphone intervention. Therefore, SaltSwitch might be better suited to primary rather than secondary prevention of CVD.
Unanswered questions and future research
The findings of the SaltSwitch trial add further data to the modest evidence base for mHealth interventions in clinical populations. 7, 8, 22, 23, 26 There were positive effects on the primary outcome (household purchases of salt from packaged foods), but no significant correlation between salt intake and systolic BP postintervention. However, given that the SaltSwitch trial was underpowered, a larger, longer-term randomised controlled trial is warranted to measure the effect on clinically important CVD risk factors such as BP.
